ANDOVER, Mass.  , Dec. 23, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 13, 2025, at 2:15 p.m. Pacific Standard Time / 5:15 p.m. Eastern Standard Time. Event: 43rd A ...

Stock Performance - TransMedics Group Inc (TMDX) shares have plunged 57.5% in the past three months, significantly underperforming the industry's 3.6% decline and the S&P 500's 8.1% growth [1] - The stock's performance has been bleak compared to peers like Medtronic plc (MDT), GE HealthCare Technologies Inc (GEHC), and Abbott Laboratories (ABT), which saw declines of 8.5%, 6.8%, and 3.6% respectively over the same period [6] Financial Performance - The company reported robust improvement in both top and bottom lines in Q3 2024, driven by increased utilization of the Organ Care System (OCS) across all three organs and additional revenues from logistics services [3] - TransMedics narrowed its 2024 revenue outlook to $428 million-$432 million, representing 77-79% growth from 2023, compared to the prior outlook of $425 million-$445 million [8] - Estimates for 2024 earnings have moved 18% south to $1.00 in the past 60 days [18] Business Developments - TransMedics appointed Mr Gerardo Hernandez as CFO, effective Dec 2, 2024 [2] - The company remains on track to achieve its target of 10,000 OCS transplant cases per year in the US by 2028 [4] - TransMedics' OCS is the only FDA-approved, portable, multi-organ, warm perfusion technology platform, with three products (OCS Heart, OCS Lung, OCS Liver) receiving pre-market approval [9] Market Position and Strategy - The company has developed strong clinical relationships with leading academic medical centers worldwide through participation in clinical trials and commercial utilization of its products [12] - TransMedics' NOP expansion includes 100% owned and operated private aircraft dedicated to organ retrieval, improving efficiency in organ procurement [11] - The OCS has been reimbursed by CMS and private insurers, with the company developing expertise in transplant reimbursement and billing [13] Product Development - TransMedics has a long history in warm machine perfusion for organ preservation and continues to add technological and usability enhancements to its devices [15] - The company plans to develop newer versions of its technology to improve ease of use, portability, and capability [15] Valuation - TransMedics' forward 12-month P/S of 4.1X is lower than the industry average of 4.5X and its five-year median of 9.9X [16] Growth Prospects - The company's strong core growth prospects and favorable Zacks Style Score with a Growth Score of B suggest continued uptrend potential [21][22] - Despite current stock performance, the company's core business strength, earnings prowess, and robust financial footing present favorable long-term opportunities [21]

In today's video, I will discuss recent updates about TransMedics (TMDX -2.36%). Watch the short video to learn more, consider subscribing, and click the special offer link below.*Stock prices used were from the trading day of Dec. 10, 2024. The video was published on Dec. 11, 2024. ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up for a free trial to Growth Stock Forum.Shares of TransMedics (NASDAQ: TMDX ) are down 60% from their August pea ...

Shares of leading organ transplant platform TransMedics (TMDX -15.65%) were down 14% as of noon ET on Wednesday, according to data provided by S&P Global Market Intelligence.TransMedics issued a positive news release yesterday evening about the hiring of Gerardo Hernandez as its new chief financial officer, but one sentence at the end of the announcement seemed to spook the market.TransMedics' tempered expectationsThis final sentence reads, "TransMedics now expects revenue for the full year 2024 to be in th ...

ANDOVER, Mass., Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024. In this role, Mr. Hernandez joins the TransMedics executive leadership team, succeeding Mr. Stephen Gordon. To enable a smooth transition, Mr. Gordon ...

Core Viewpoint - TransMedics Group (TMDX) is a significant player in organ transplant therapy, but its premium valuation raises concerns in the current market context [1] Group 1: Company Performance - TMDX's shares have declined by 52.3% over the past three months, underperforming the Medical – Instruments sector's decline of 4% and the S&P 500's gain of 7.1% [3] - Despite a reported 64% revenue growth in Q3, TMDX's performance fell short of expectations by 4.8%, with earnings per share (EPS) of 12 cents missing market expectations by 57.1% [6] - The company has maintained its full-year revenue guidance of $425-$445 million, anticipating a recovery in the U.S. transplant market despite recent lower-than-expected sales [7] Group 2: Market Conditions - The U.S. transplant market has shown softness, leading to declining volumes for TMDX in recent quarters [6] - TMDX's gross margin contracted by 500 basis points to 56% in Q3 compared to the previous year, indicating rising costs that may persist [8] Group 3: Competitive Landscape - TMDX holds a competitive advantage with its warm physiologic portable technology for organ preservation, which outperforms competitors like Xvivo in terms of storage duration [12] - The company plans to launch its own OCS cold perfusion technology for the heart, further enhancing its competitive edge [12] Group 4: Future Outlook - The Zacks Consensus Estimate for TMDX's 2024 earnings is $1.00 per share, reflecting a projected year-over-year improvement of nearly 230%, although estimates have declined by 18% over the past 60 days [10] - Current market conditions and potential regulatory changes with a new U.S. President may impact TMDX's future sales and profit margins [9]

ANDOVER, Mass., Nov. 26, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that it will host an Investor & Analyst Day in New York City on Tuesday, December 10, 2024, at 10:00 AM ET.Waleed Hassanein, MD., President and Chief Executive Officer, and members of the leadership team will present an overview of TransMedics' growth strateg ...

This growth stock has been on my watchlist for a while and might soon be included in my portfolio.In this video, I will talk about recent updates regarding TransMedics (TMDX 3.34%). Watch the short video to learn more, consider subscribing, and click the special offer link below.*Stock prices used were from the trading day of Nov. 22, 2024. The video was published on Nov. 24, 2024. ...

ANDOVER, Mass., Nov. 19, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference at the Lotte New York Palace. The fireside chat will take place on Tuesday, December 3, 2024, at 4:00 p.m. Eastern Time.Eve ...